Company: RGNT
Filing Date: 2025-01-24
Form Type: DRS
Source: 0001213900-25-006245
Chunk: 123

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-01-24
Form: DRS
Chunk 123
---
 2025. In various countries, patent term extension or supplementary protection certificates are
available upon receipt of marketing approval to prolong the period of exclusivity of a new medical product. The earliest patent family
of the Company derived from WO 2005/061018 includes patents Nos. US 7,842,667, US 8,007,774, US 8,858,925, US 9,120,872, US 9,474,830,
US 9,700,600 and EP 1870115, which are detailed in the table below.

While the first family
of patents form the “basic patent estate” covering the current products of the Company, diligent efforts have been made
by the Company to cover improvements and alternatives. Our “basic patent estate” has expiration date in December 2025.
Although the patents included in this “basic patent estate” are close to expiring, such patents only cover certain
components in the Company’s products. Our additional subsequently granted patents provide supplementary protection, as well as
the latest pending patent applications which cover subsequent improvements in the Company’s products and processes.
Furthermore, regulatory approval, when obtained, will yield certain types of non-patent exclusivities that can maintain the
Company’s advantage even after expiration of the earlier “basic patent estate”.

<div align='center'>75</div>

We also have additional subsequent
patents that we believe could prevent competitors from entering the market when patents directed to the specific conjugate molecules expire.
The additional patents are directed to manufacturing processes, formulations and other important technologies and serve to support and
extend patent protection beyond the earliest patents. While it is a fact that the earliest patent families are due to expire in the next
few years, we believe that the newest patent applications will provide protection to the updated products and processes for their manufacture.
The latest patent applications, some of which have matured to patents, are designed to protect various improvements to the earliest filed
patents, including improvements to the process of production, and ready to use formulations that may be administered from pre-filled syringes
and do not require addition of activators prior to use.

The latest family of patent
applications is derived from WO 2017/103924 (filed in China and in other territories), and the objectives the Company aims to achieve
with these applications are to seek to obtain patent protection to cover improved compositions which are being used or which may be used
by the Company in the future. The improved compositions